- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03502174
FreeStyle Libre Glucose Monitoring System in Pediatric Populations
24. januar 2019 oppdatert av: Abbott Diabetes Care
FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations
This study is a non-randomized, single-arm, multi-center study that is designed to evaluate the safety and effectiveness of the FreeStyle Libre Flash Glucose Monitoring Systems in pediatric populations.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Up to 85 subjects will be enrolled at up to four (4) clinical research sites in the United States.
Subjects will wear two Sensors.
Each Sensor will have a paired Reader that will be given to the subject.
All Readers will be masked during the study (i.e.
subjects will not be able to view glucose results obtained from the Sensor on the Reader screen).
Subjects will be asked to perform at least 4 capillary Blood Glucose (BG) tests per day using the primary Reader.
Interstitial glucose readings from each Sensor will be obtained with the corresponding Readers immediately following each BG test.
Subjects will be instructed to report any problems with the device.
Subjects will make four (4) to five (5) scheduled visits to the clinical study site, including the Enrollment/Screening Visit (Visit 1).
Based on the subjects weight, subjects will have up to two (2) in-clinic visits during which intravenous blood draws and YSI reference testing will occur.
Studietype
Observasjonsmessig
Registrering (Faktiske)
63
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
California
-
Santa Barbara, California, Forente stater, 93105
- Sansum Diabetes Research Institute
-
Walnut Creek, California, Forente stater, 94598
- Diablo Clinical Research
-
-
Idaho
-
Idaho Falls, Idaho, Forente stater, 83404
- Rocky Mountain Diabetes & Osteoporosis Center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
6 år til 17 år (Barn)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Subjects aged 6-17 years, with type 1 or type 2 diabetes who currently perform capillary blood glucose (BG) testing at least four (4) times a day.
Beskrivelse
Inclusion Criteria:
- Subject must be at least 6 years of age.
- Subject must weigh at least 26 kg (57.2 lbs.).
- Subject must have a diagnosis of type 1 or type 2 diabetes mellitus
- Subject must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily).
- Subject must be currently performing at least four (4) capillary blood glucose tests per day.
- Subject is willing to perform a minimum of 4 finger sticks per day during the study.
- Subject is willing to allow medical personnel to insert at IV catheter in the arm to allow for venous blood samples to be obtained per the study protocol.
- Subject and/or guardian must be able to read and understand English.
- In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
- Subject must be available to participate in all study visits.
- Subject must be willing and able to provide written signed and dated informed assent when appropriate.
- Subject's parent, guardian or legally authorized representative must be willing and able to provide written informed consent.
Exclusion Criteria:
- Subject is 18 years of age or older.
- Subject weighs less than 26 kg (57.2 lbs.).
- Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
- Subject is known to be pregnant or becomes pregnant during the study (applicable to female subjects only).
- Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.
- Subject is currently participating in another clinical trial.
- Subject has had significant blood loss within 112 days (3.7 months) prior to the beginning of the study activities subjects.
- Subject is anemic, defined as having hemoglobin levels below 11.5 g/dL for subjects aged 6-11 years old, less than 12.0 g/dL for subjects aged 12-15 years old, less than 12.0 g/dL for females aged 15-17 and less than 13.0 g/dL for males aged 15-171, or as determined by investigator.
- Subject has X-ray, MRI or CT appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.
- Subject is unsuitable for participation due to any other cause as determined by the Investigator.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
FreeStyle Libre Flash Glucose Monitoring System Performance
Tidsramme: up to 14 days
|
System performance will be characterized with respect to YSI reference venous plasma sample measurements.
Point accuracy of the system will be evaluated as the proportion of System readings that are within ±20% of the YSI reference value for YSI glucose levels ≥ 80 mg/dl and within ±20 mg/dl for YSI glucose levels <80 mg/dl.
|
up to 14 days
|
|
FreeStyle Libre Flash Glucose Monitoring System Related adverse device effects
Tidsramme: up to 45 days
|
System will be characterized by Adverse Device Effects and Serious Adverse Device Effects experienced by study participants.
|
up to 45 days
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studieleder: Shridhara Alva, PhD, Abbot Diabetes care inc.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
5. april 2018
Primær fullføring (Faktiske)
3. juli 2018
Studiet fullført (Faktiske)
3. juli 2018
Datoer for studieregistrering
Først innsendt
4. april 2018
Først innsendt som oppfylte QC-kriteriene
17. april 2018
Først lagt ut (Faktiske)
18. april 2018
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
28. januar 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
24. januar 2019
Sist bekreftet
1. april 2018
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- ADC-US-VAL-18172
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Ja
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sukkersyke
-
State University of New York at BuffaloMedical University of South CarolinaFullførtSukkersyke | Type 2 diabetes mellitus | Voksendiabetes mellitus | Ikke-insulinavhengig diabetes mellitus | Ikke-insulinavhengig diabetes mellitus, type IIForente stater
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.FullførtDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinavhengig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinavhengig diabetes mellitus 1 | Diabetes mellitus, insulinavhengig, 1 | Diabetes mellitus, sprø | Diabetes mellitus... og andre forholdForente stater
-
Superior UniversityAktiv, ikke rekrutterendeType 2 diabetes mellitus 1Pakistan
-
Meir Medical CenterFullførtDiabetes mellitus type 2 | Diabetes mellitus, ikke-insulinavhengig | Diabetes mellitus, om oral hypoglykemisk behandling | Voksen type diabetes mellitusIsrael
-
Peking Union Medical College HospitalUkjentType 2 diabetes mellitus | Type 1 diabetes mellitus | Svangerskapsdiabetes mellitus | Pankreatogen diabetes mellitus | Pregestasjonell diabetes mellitus | Diabetespasienter i perioperativ periodeKina
-
Guang NingRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitus | Monogenetisk diabetes | Pankreatogen diabetes | Legemiddelindusert diabetes mellitus | Andre former for diabetes mellitusKina
-
SanofiFullførtType 1 Diabetes Mellitus-Type 2 Diabetes MellitusUngarn, Den russiske føderasjonen, Tyskland, Polen, Japan, Forente stater, Finland
-
Hoffmann-La RocheRoche DiagnosticsFullførtDiabetes mellitus type 2, diabetes mellitus type 1Tyskland
-
Vanderbilt University Medical CenterRekrutteringHyperglykemi | Type 2 diabetes mellitus (T2DM) | Type 1 diabetes mellitus (T1DM)Forente stater
-
University of California, San FranciscoJuvenile Diabetes Research FoundationFullførtType 1 diabetes mellitus | Diabetes mellitus, type I | Insulinavhengig diabetes mellitus 1 | Diabetes mellitus, insulinavhengig, 1 | IDDMForente stater, Australia
Kliniske studier på FreeStyle Libre Flash-glukoseovervåkingssystem
-
Abbott Diabetes CareFullførtSukkersykeForente stater
-
University Medical Centre LjubljanaFullførtSvangerskapsdiabetes mellitus (GDM)Slovenia
-
Poitiers University HospitalUkjentInsulinbehandlet type 2 diabetes med høy risiko for hypoglykemiFrankrike